AAM Statement on Considered Expansion of Antitrust Lawsuit Against Generic Drugmakers

WASHINGTON, DC (October 31, 2017) – AAM and our member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients.

AAM is fully committed to compliance with all laws and ethical business practices.

Attribution: Jeff Francer, Senior Vice President and General Counsel

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.